This technology is a comprehensive compound design and preclinical testing platform that can be used to develop multifunctional drugs for Alzheimer’s disease, and has already led to the development of several promising lead compounds.
This technology is a tool to identify compounds that block the activity of TIA1, an RNA-binding protein that regulates stress granule formation and the generation of pathological forms of tau protein, and is implicated in a range of neurodegenerative diseases.
This technology, FixR, is a modified peptide and delivery system aimed at reducing pathogenic late sodium currents, which are implicated in cardiac and neurological diseases, including cardiac arrhythmia.
This technology is a small molecule protein therapeutic for systolic heart failure, which improves contractility without an unwanted rise in a patient’s heart rate.
This technology is a method of reprogramming cellular metabolism to treat neurodegenerative disorders by downregulating catabolism and upregulating anabolism in cells.
This technology is an immunosuppressant that suppresses T cell proliferation and can be used to treat organ transplant rejection and autoimmune or inflammatory conditions.
This technology is a small molecule that selectively targets the mitogen-activated protein kinase (MAPK) core pathways, regulated by Germinal Center Kinase (GCK), and inhibits cell growth for the treatment of cancers, notably multiple myeloma.
This technology uses S-methyl-L-Thiocitrulline, a neuronal nitric oxide synthase inhibitor, and its derivatives as a pharmacological treatment for the prevention and treatment of myopia.
